* * * * * * * * * * *
Home » News » News item details

Anyplex™ II – HPV DNA Detection

17 March 2017

Human papillomavirus (HPV) has been identified as the leading cause of cervical cancer in women. Over 150 different HPV types have been identified but only a subset are implicated as major risk factors for cervical cancer such as HPV types 16 and 18. Co-infection of high risk and low risk HPV types have now been identified as a risk factor for increased morbidity and disease progression. Outcome-based clinical studies regarding HPV vaccines have demonstrated the advantages of long-term monitoring of infected HPV’s in association with persistent efficacy and cross-genotype protection. Anyplex™ II overcomes the limitations of other products in the market by offering a more comprehensive subtyping capability.

Seegene is the world's leading developer of multiplex IVD products. Seegene's innovative proprietary technologies, including DPO™, TOCE™ and MuDT™, can simultaneously detect up to 28 targets per sample with no post PCR processing, with high sensitivity, specificity, and reproducibility. 

MAST® is pleased to announce two HPV assays from Seegene:

Anyplex™ II HPV 28 differentiates and quantifies 19 high risk and 9 low risk HPV genotypes. Not only will the assay give the most comprehensive genotyping available on the market but it achieves this with only 2 tubes, no post PCR processing and automatically interprets the results for the user!

Anyplex™ II HPV HR is a fast, reliable, and quantitative test for the detection, differentiation, and quantification of 14 high risk HPV genotypes in a single tube. AnyplexTM II HPV HR overcomes limitations of existing screening platforms by genotyping beyond 16, 18 and ‘other’ to give the clinician a more complete picture, without any loss of throughput or additional labour required.

Features Include

  • Accurate genotyping of multiple HPV genotypes in a single reaction
  • Multiplex real-time PCR with high sensitivity and specificity by utilization of DPO™ and TOCE™ technologies
  • Quantitative analysis by cyclic- CMTA
  • High and Medium throughput automated solutions with end to end sample tracking and minimal hands on requirement
  • Utilization of the UDG system to prevent carry-over contamination
  • Endogenous Internal Control for assay validity
  • Convenient data interpretation by Seegene Viewer

For more information please contact


« Back



Home | Contact us | Terms and Conditions

Our site uses cookies to enhance visitor experience.